The Plantar Fasciitis Treatment by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Plantar Fasciitis Treatment Market:
https://www.thebusinessresearchcompany.com/report/plantar-fasciitis-treatment-global-market-report
According to The Business Research Company’s Plantar Fasciitis Treatment, The plantar fasciitis treatment market size has grown exponentially in recent years. It will grow from $1.34 billion in 2023 to $1.67 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to alternative therapies, patient education and awareness, pain management solutions, rise in sports injuries, physical therapy techniques..
The plantar fasciitis treatment market size is expected to see exponential growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to regulatory changes and approvals, patient-centric approaches, research and clinical trials, focus on personalized medicine, growing aging population.. Major trends in the forecast period include focused rehabilitation techniques, innovations in orthopedic devices, biomechanical studies, alternative therapies advancements, patient education and self-care..
A rise in obesity is expected to propel the growth of the plantar fasciitis market going forward. Obesity is a health risk caused by an abnormal or excessive fat buildup. Overweight is defined as a body mass index (BMI) of 25 or greater and obesity as a BMI greater than 30. A person with a normal weight has a chance of acquiring plantar fasciitis that is almost six times lower than that of someone with a body mass index (BMI) of 30 or higher. For instance, in January 2023, according to a report shared by Forbes, a US-based business magazine, During the COVID-19 pandemic, the obesity rate in the United States increased by 3% between March 2020 and March 2021. Therefore, the rise in obesity is driving the growth of the plantar fasciitis market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9385&type=smp
The plantar fasciitis treatment market covered in this report is segmented –
1) By Type: Medication Therapy, Orthotics, Shockwave Therapy, Surgery, Other Types
2) By Diagnosis: Medical History, Physical Examination, X-Rays, Radiography, Other Diagnosis
3) By End User: Hospitals, Clinics, Other End Users
Technological advancements are a key trend gaining popularity in the plantar fasciitis treatment market. Major companies operating in the plantar fasciitis treatment market are developing and implementing new technologies to revolutionize treatment for plantar heel pain and expanding their geographic presence to sustain their position in the market. For instance, in December 2022, ZetrOZ Systems, a US-based ultrasound technology manufacturing company, introduced the Sam X1, the only wireless ultrasound device with FDA certification for at-home usage. The Sam X1 wireless unit can be used as a regenerative treatment alternative for soft tissue injuries and plantar fasciitis to boost cellular proliferation without the use of drugs or surgery. It has been proven effective in treating a wide range of injuries, including plantar fasciitis. The ZetrOZ sam x1 device widens blood vessels to deliver more oxygenated blood to the healing region, eliminating waste products such as cytokine enzymes and cells, and speeding up the healing process.
The plantar fasciitis treatment market report table of contents includes:
1. Executive Summary
2. Plantar Fasciitis Treatment Market Characteristics
3. Plantar Fasciitis Treatment Market Trends And Strategies
4. Plantar Fasciitis Treatment Market - Macro Economic Scenario
5. Global Plantar Fasciitis Treatment Market Size and Growth
6. Plantar Fasciitis Treatment Market Segmentation
7. Plantar Fasciitis Treatment Market Regional And Country Analysis
.
.
.
27. Plantar Fasciitis Treatment Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Plantar Fasciitis Treatment Market
29. Plantar Fasciitis Treatment Market Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Bayer AG
- Superfeet Worldwide LLC
- Bauerfeind AG
- Ottobock SE & Co. KGaA
- Shapecrunch Technology Pvt. Ltd.
- Sanofi SA
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
According to the report, the global plantar fasciitis treatment market was valued at ~ US$ 695 Mn in 2018, and is projected to expand at a CAGR of 4.3% from 2019 to 2027.
Rise in the patient population and surge in the adoption of technologically-advanced products are the major factors anticipated to drive the global plantar fasciitis treatment market from 2019 to 2027.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=47658Increase in Burden of Patient Population to Drive Plantar Fasciitis Treatment MarketPlantar fasciitis is one of the most common foot pain conditions.
Plantar fasciitis is primarily caused due to repetitive strain on the ankle, leading to progressive wear and tear and degeneration of plantar fascia, a thick connective tissue covering the lower side of the foot.The obese and geriatric populations are more prone to plantar fasciitis.
It leads to sharp pain and other complications, in which, plantar fascia, a tissue connecting the heel and the toe bones becomes less flexible and more constrained.Rise in the number of individuals living sedentary lifestyles coupled with changes in eating habits leads to an increase in obesity, which puts pressure on the joints and ankles, and can result in plantar fasciitis.Increase in the percentage of geriatric and obese populations is likely to propel the number of patients suffering from plantar fasciitis.Moreover, prolonged standing, weight bearing, ill-fitted shoes, incorrect walking posture, and sudden rise in sports activities can trigger micro-tears in the plantar fascia, and lead to plantar fasciitis.This multi-factorial etiology of the disease is anticipated to drive the global plantar fasciitis treatment market during the forecast period.Request COVID Analysis on Plantar Fasciitis Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=47658Orthotics Treatment Type to Gain Market Share and offer Lucrative OpportunitiesThe report offers detailed segmentation of the global plantar fasciitis treatment market based on type, end user, and region.
Increase in the penetration of leading players in the region is expected to boost the plantar fasciitis treatment market in the region during the forecast period.The plantar fasciitis treatment market in Asia Pacific is primarily driven by the surge in investments in healthcare infrastructure, rise in disposable income of people, economic growth, large population base with chronic diseases & other foot pain conditions, and expansion in the distribution networks of leading players in the region to establish themselves in lucrative plantar fasciitis treatmentBuy Continuous Plantar Fasciitis Treatment Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=47658=SDr.
These include Hanger, Inc., Bayer Group (Dr. Scholl's), A. Algeo Limited, Bauerfeind AG, Superfeet Worldwide, Inc., Ottobock SE & Co. KGaA (Ottobock Holding), Pfizer, Inc., Sanofi, and GlaxoSmithKline plc.Hanger, Inc. is a U.S.-based manufacturer and distributor of orthotic and prosthetic devices, and provides therapeutic solutions to patients and businesses in acute, post-acute, and clinic settings.
